{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:47:26Z","timestamp":1785466046441,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00520-014-2556-x","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T06:28:51Z","timestamp":1418797731000},"page":"2019-2024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction"],"prefix":"10.1007","volume":"23","author":[{"given":"Michael J.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Vargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Shaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Layman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Macrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Mrozek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvaneswari","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam B.","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"2556_CR1","unstructured":"Taxol\u00ae injection (package insert). Princeton, NJ: Bristol-Myers Squibb Company; July 2007"},{"issue":"16","key":"2556_CR2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663\u20131671","journal-title":"N Engl J Med"},{"issue":"26","key":"2556_CR3","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666\u20132676","journal-title":"N Engl J Med"},{"issue":"7","key":"2556_CR4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s004320050297","volume":"125","author":"M Markman","year":"1999","unstructured":"Markman M et al (1999) An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 125(7):427\u2013429","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6 Suppl 19","key":"2556_CR5","first-page":"S19-13","volume":"24","author":"MA Bookman","year":"1997","unstructured":"Bookman MA et al (1997) Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Semin Oncol 24(6 Suppl 19):S19-13\u2013S19-15","journal-title":"Semin Oncol"},{"key":"2556_CR6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.bjc.6601303","volume":"90","author":"JS Kloover","year":"2004","unstructured":"Kloover JS et al (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of pre-medication regimens. Br J of Cancer 90:304\u2013305","journal-title":"Br J of Cancer"},{"key":"2556_CR7","unstructured":"Micromedex. Diphenhydramine. v 1.0 2007. Available at: http:\/\/www.thomsonhc.com\/micromedex2\/librarian . Accessed March 2007"},{"issue":"5\u20136","key":"2556_CR8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1081\/CNV-120003535","volume":"20","author":"J Quock","year":"2002","unstructured":"Quock J et al (2002) Premedication strategy for weekly paclitaxel. Cancer Invest 20(5\u20136):666\u2013672","journal-title":"Cancer Invest"},{"issue":"3","key":"2556_CR9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000055093","volume":"24","author":"H Koppler","year":"2001","unstructured":"Koppler H et al (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24(3):283\u2013285, English, German","journal-title":"Onkologie"},{"issue":"2\u20133","key":"2556_CR10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000085618","volume":"51","author":"AS Braverman","year":"2005","unstructured":"Braverman AS et al (2005) Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. Chemotherapy 51(2\u20133):116\u2013119","journal-title":"Chemotherapy"},{"issue":"5","key":"2556_CR11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12(5):601\u2013609","journal-title":"Oncologist"},{"issue":"9","key":"2556_CR12","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00520-011-1303-9","volume":"20","author":"MJ Berger","year":"2012","unstructured":"Berger MJ et al (2012) Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 20(9):1991\u20131997","journal-title":"Support Care Cancer"},{"issue":"1","key":"2556_CR13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman M et al (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18(1):102\u2013105","journal-title":"J Clin Oncol"},{"issue":"10","key":"2556_CR14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00002018-200124100-00005","volume":"24","author":"KM Zanotti","year":"2001","unstructured":"Zanotti KM, Markman M (2001) Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 24(10):767\u2013779","journal-title":"Drug Saf"},{"issue":"3","key":"2556_CR15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","volume":"96","author":"AM Feldweg","year":"2005","unstructured":"Feldweg AM et al (2005) Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 96(3):824\u2013829","journal-title":"Gynecol Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2556-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-014-2556-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2556-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T14:31:22Z","timestamp":1566138682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-014-2556-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["2556"],"URL":"https:\/\/doi.org\/10.1007\/s00520-014-2556-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}